RESEARCH PEPTIDE FUNDAMENTALS
Which Peptide Actually Matches the Problem?
A practitioner-blunt map from a specific research question — tissue repair, the growth-hormone axis, metabolic signaling, sexual desire, weight regulation — to the peptide actually studied for it, and how far that evidence really goes.
BPC-157
The lead compound on this map — a gastric-derived peptide studied almost entirely in animal models for tendon, ligament, and gut-lining repair, with human evidence still limited to a handful of small pilot reports.
Read the research →
CJC-1295
A long-acting analog of growth-hormone-releasing hormone, with real human pharmacology data showing sustained GH and IGF-1 elevation — but no approval and no long-term safety trial.
Read the research →
MOTS-c
A peptide the body's own mitochondria already encode, studied in mice for metabolic and exercise signaling — with human evidence limited to a single observational cohort.
Read the research →
PT-141
An FDA-approved melanocortin-receptor agonist for hypoactive sexual desire disorder in premenopausal women — the only compound here approved for exactly this purpose.
Read the research →
Tirzepatide
The first approved dual GIP/GLP-1 receptor agonist, with the deepest human trial record of any compound on this map and a real, well-documented side-effect profile.
Read the research →The short version
My Peptide Solution exists to answer one blunt question: given a specific problem — a stubborn tendon, a growth-hormone question, a metabolic target, a sexual-desire concern, or a longevity curiosity — which research peptide is actually being studied for it, and how far does that research really reach? This site walks through five of the most-searched research peptides: BPC-157 (tissue repair), CJC-1295 (growth-hormone axis), MOTS-c (metabolic and longevity signaling), PT-141 (sexual desire), and tirzepatide (metabolic and weight regulation).
Each compound gets the same plain accounting: what it is, how it is proposed to work, what the published literature actually reports, and where the evidence runs out. None of this is medical advice, none of it recommends a human dose, and none of it tells anyone what to do. It is a map from problem to peptide to evidence — read it, then talk to a clinician.
What are research peptides?
Peptides are short chains of amino acids — smaller than proteins, built from the same building blocks. The five compounds mapped here span very different biology: BPC-157 is a gastric-derived cytoprotective peptide studied mostly in animal injury models; CJC-1295 is a synthetic analog of growth-hormone-releasing hormone; MOTS-c is a peptide encoded inside mitochondrial DNA that regulates metabolism under stress; PT-141 (bremelanotide) is a melanocortin-receptor agonist approved for one specific indication in women; and tirzepatide is an FDA-approved dual-incretin-receptor agonist for diabetes and weight management.
Only two of the five — PT-141 and tirzepatide — are approved prescription medicines with defined human indications. BPC-157, CJC-1295, and MOTS-c are unapproved research chemicals: legal to buy for laboratory use, not legal or advisable to inject into a person outside a clinical trial. This site reports dosing only exactly as a cited study used it — never as a suggestion for what to do.
How this problem-to-peptide map works
Rather than organize by drug class, this desk organizes by the problem someone is usually trying to solve, because that is how most people arrive at a peptide search in the first place.
- BPC-157 is the entry point for a soft-tissue or gut problem — the peptide most associated in animal and small pilot studies with accelerated repair of tendon, ligament, and gastric-lining injury, though a 2025 narrative review is blunt that only three small human pilot studies exist and rigorous trials are lacking [2].
- CJC-1295 is the entry point for a growth-hormone-axis question — a long-acting GHRH analog shown in small human pharmacology studies to raise GH and IGF-1 for days per dose while preserving the body's normal pulsatile GH pattern [11].
- MOTS-c is the entry point for a metabolic or longevity question — a mitochondrial-encoded peptide whose best human data are biomarker associations, not interventional trials, as a 2023 review makes clear [15].
- PT-141 is the entry point for a sexual-desire problem — the only compound on this map approved by the FDA for that specific indication, in premenopausal women with HSDD, following two Phase 3 trials [20].
- Tirzepatide is the entry point for a metabolic or weight-regulation problem — a dual GIP/GLP-1 receptor agonist that beat the prior GLP-1-only standard head-to-head in a 2025 trial [23].
Use the individual pages to read each compound in full, or jump straight to the comparison page to see all five side by side.
A note on how this desk reads the literature
My Peptide Solution is a cross-referenced literature digest, not a store. Every claim traces to a numbered source on the shared references list. The five compounds sit at wildly different points on the evidence-maturity spectrum, and this desk does not blur that line to make any of them sound more settled than it is: two are FDA-approved prescription drugs with large trial programs, and three are unapproved research chemicals whose human evidence ranges from thin to nonexistent. Where a compound's benefit or side-effect profile comes from community reports rather than a clinical trial, it is labeled as anecdotal, not clinical evidence, every time it appears. The goal is a disciplined account of what is known and how confidently it is known, so a reader can calibrate their own understanding rather than simply absorbing a conclusion.